Q3 Earnings Forecast for ATXS Issued By Lifesci Capital

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Investment analysts at Lifesci Capital issued their Q3 2025 EPS estimates for shares of Astria Therapeutics in a report issued on Wednesday, August 13th. Lifesci Capital analyst S. Slutsky anticipates that the biotechnology company will post earnings of ($0.28) per share for the quarter. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. Lifesci Capital also issued estimates for Astria Therapeutics’ FY2025 earnings at ($1.81) EPS.

Several other brokerages have also recently commented on ATXS. JMP Securities boosted their price target on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a “market outperform” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and set a $47.00 price target on shares of Astria Therapeutics in a research report on Wednesday, May 14th. Finally, Citigroup reissued an “outperform” rating on shares of Astria Therapeutics in a research report on Wednesday. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $29.00.

Astria Therapeutics Trading Up 1.3%

ATXS opened at $6.85 on Friday. The firm’s fifty day simple moving average is $6.23 and its 200 day simple moving average is $5.76. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.92. The stock has a market capitalization of $386.61 million, a P/E ratio of -3.41 and a beta of 0.48.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.04.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ATXS. JPMorgan Chase & Co. increased its stake in shares of Astria Therapeutics by 39.6% during the 4th quarter. JPMorgan Chase & Co. now owns 54,664 shares of the biotechnology company’s stock worth $489,000 after purchasing an additional 15,520 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Astria Therapeutics by 47.3% during the 4th quarter. Wells Fargo & Company MN now owns 23,569 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 7,563 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Astria Therapeutics by 7.6% during the 4th quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 2,222 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Astria Therapeutics during the 4th quarter worth about $707,000. Finally, Barclays PLC increased its stake in shares of Astria Therapeutics by 5.6% during the 4th quarter. Barclays PLC now owns 97,820 shares of the biotechnology company’s stock worth $875,000 after purchasing an additional 5,169 shares during the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.